STOCK TITAN

GeneDx Holdings Corp - WGS STOCK NEWS

Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.

GeneDx Holdings Corp (NASDAQ: WGS) drives innovation in genomic medicine through advanced sequencing technologies and clinical decision support tools. This news hub provides investors and healthcare professionals with essential updates on the company's progress in transforming rare disease diagnosis and precision medicine.

Access authoritative reports covering earnings announcements, research collaborations, regulatory milestones, and technology advancements. Our curated collection includes press releases about clinical study validations, healthcare system partnerships, and innovations in rapid whole genome sequencing applications.

Stay informed about developments in pediatric genetics, oncology diagnostics, and data integration initiatives that demonstrate GeneDx's leadership in translating genomic insights into actionable health solutions. Regular updates ensure you never miss critical information about diagnostic capabilities expansion or strategic growth in the genomic testing market.

Bookmark this page for direct access to verified updates and analysis-free reporting on WGS's role in advancing evidence-based genetic medicine. Check back frequently to monitor how GeneDx continues to shape the future of personalized healthcare through cutting-edge science and clinical partnerships.

Rhea-AI Summary
GeneDx (WGS) to Participate in Cowen Healthcare Conference, Hosting Fireside Chat on March 6, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences
-
Rhea-AI Summary
GeneDx Holdings Corp. (WGS) reported strong fourth quarter 2023 financial results with revenue of $58.1M, 68% growth in exome and genome test revenue, and adjusted gross margins of 56%. The company narrowed its adjusted net loss to $17.8M and reduced cash burn by 51% year-over-year. GeneDx issued guidance for FY 2024 revenue between $220M and $230M and aims for profitability in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.63%
Tags
-
Rhea-AI Summary
GeneDx (Nasdaq: WGS) will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024. The management will host a conference call to discuss 2023 financial and operating results and share full year 2024 guidance at 4:30 p.m. Eastern Time. Investors can register online to listen to the conference call and access the live and archived webcast on the GeneDx investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
conferences earnings
Rhea-AI Summary
GeneDx announced the granting of 106,030 restricted stock units (RSUs) to newly hired employees as inducements, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, subject to continued service with the company. Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.98%
Tags
none
-
Rhea-AI Summary
GeneDx Holdings Corp. (Nasdaq: WGS) expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations of more than $57M, with at least 63% year-over-year revenue growth for exome and genome test revenue. The company reduced fourth quarter 2023 cash burn by 51% year-over-year and 21% sequentially, ending December 31, 2023, with a cash position of at least $131 million. GeneDx is reiterating the path to profitability in 2025, with a strong focus on improving health outcomes through genomic and clinical insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.36%
Tags
-
Rhea-AI Summary
GeneDx (Nasdaq: WGS) presents new data at the American Epilepsy Society (AES) annual meeting, showing exome sequencing offers superior clinical results compared to multi-gene panels for patients with epilepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
Rhea-AI Summary
GeneDx (Nasdaq: WGS) to Participate in Evercore ISI HealthCONx Conference, President and CEO to Speak at Fireside Chat
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
conferences
-
Rhea-AI Summary
GeneDx (GDXX) Grants 10,000 RSUs to Newly Hired Employees Under 2023 Equity Inducement Plan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary

Boston Dynamics, a leader in mobile robotics, announced the launch of their new robot, Stretch, designed for warehouse automation. The robot is equipped with a smart gripper and advanced vision system, offering flexibility and efficiency in handling a wide range of products. With the increasing demand for e-commerce and logistics automation, Stretch is poised to revolutionize warehouse operations, reducing manual labor and increasing productivity. This innovative solution aligns with the company's commitment to advancing robotics technology and addressing evolving industry needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.95%
Tags
management
Rhea-AI Summary
GeneDx Holdings Corp. reported total revenue of $53M with over 40% YoY growth in exome and genome test revenue. Gross margins expanded to 48% in continuing operations and cash burn reduced by 52% YoY. The company secured a $75M debt facility and initiated a $40M cost savings plan. Updated guidance projects $187-$192M in FY 2023 revenue and profitability in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.34%
Tags
GeneDx Holdings Corp

Nasdaq:WGS

WGS Rankings

WGS Stock Data

2.60B
24.97M
12.71%
87.98%
9%
Diagnostics & Research
Services-health Services
Link
United States
STAMFORD